No abstract available.
Colitis ; Humans ; Immunosuppressive Agents

No abstract available.
Herpes Zoster* ; Humans ; Immunosuppressive Agents*

No abstract available.
Adult* ; Humans ; Immunosuppressive Agents* ; Nephrotic Syndrome*

No abstract available.
Cyclosporine ; Humans ; Immunosuppressive Agents* ; Psoriasis* ; Sarcoma, Kaposi*

No abstract available.
Cyclosporine ; Humans ; Immunosuppressive Agents* ; Psoriasis* ; Sarcoma, Kaposi*

Study on white mices with age of 6-8 weeks, 18-20g body weight. They were divided into 3 groups: group 1 (control group): 30 mices; group 2: mices were immunesuppressed by 200mg cyclophosphamid per one kilogram of body weight, being checked after 5 days of injection; and 300mg cyclophosphamid per one kilogram (200mg on the first day and 100mg on the fifth day) and it was checked after 10 days of injection (group 3). The results: immunesuppressed model implemented by intraperitonial injection of 200mg per one kilogram of body weight checked after 5 days of injeciton. These parameters were used to assign the immune function
Immunosuppressive Agents ; Mice ; Animal Experimentation ; Cyclophosphamide

Tacrolimus (FK506) is a 23-membered macrolide with immunosuppressant activity that is widely used clinically for treating the rejection after organ transplantation. The research on tacrolimus production was mainly focused on biosynthesis methods, within which there are still some bottlenecks. This review summarizes the progress made in tacrolimus biosynthesis via modification of metabolic pathways and control of fermentation process, with the hope to address the technical bottlenecks for tacrolimus biosynthesis and improve tacrolimus production by fermentation engineering and metabolic engineering.
Tacrolimus ; Immunosuppressive Agents ; Fermentation ; Macrolides ; Anti-Bacterial Agents

No abstract available.
Bone Marrow Transplantation* ; Bone Marrow* ; Immunosuppressive Agents ; Myelitis, Transverse*

Necrotizing fasciitis (NF) is an uncommon, life-threatening infection of the subcutaneous tissue and superficial fascia. The clinical course of NF is rapid and progressive, and it is often fatal despite the appropriate therapy. The prognosis of NF depends on a timely diagnosis and then proper treatment. At onset it may not be possible to clearly distinguish NF from minor soft-tissue infections. Although infection are common due to the use of steroids and immunosuppressive agents in patients with systemic lupus erythematous (SLE), it is interesting that NF has rarely been reported with SLE. Here, we present two cases of NF with SLE.
Fasciitis, Necrotizing ; Humans ; Immunosuppressive Agents ; Prognosis ; Steroids ; Subcutaneous Tissue

PURPOSE: Pigs are promising donor species for xenotransplantation. This study was performed to examine acute cyclosporine (CsA) nephrotoxicity in a pig model. METHODS: Adult pigs were treated daily for 1 week with vehicle (VH), or 7.5 mg/kg (CsA7.5), 15 mg/kg (CsA15), and 30 mg/kg (CsA30) CsA. The renal function, electrolyte levels, whole- blood CsA levels, and histopathological results (vacuolization and tubulointerstitial fibrosis) were compared among the different treatment groups. RESULTS: After 1 week of treatment, it was found that CsA induced characteristic lesions that were remarkably similar to those of chronic CsA nephropathy in humans. Compared with the results obtained for the VH group, CsA reduced renal function and yielded poor histopathological results. With an increase in the CsA concentration, the renal function and histological parameters worsened in a dose-dependent manner. CONCLUSION: The study showed that CsA dose-dependently induced renal injury in a pig model. These results provide basic data to estimate or prevent the adverse renal effects of immunosuppressants during porcine xenotransplantation in the future.
Adult ; Cyclosporine* ; Humans ; Immunosuppressive Agents ; Swine ; Tissue Donors ; Transplantation, Heterologous